论文部分内容阅读
目的观察奥扎格雷钠注射液对急性脑梗死患者的临床疗效及对血清MMP-9水平的影响。方法 65例急性脑梗死患者随机分成奥扎格雷钠组(31例)和常规治疗组(34例),两组均给予常规治疗,奥扎格雷钠组加用奥扎格雷钠注射液80mg,每日2次静滴,疗程14d。采用ELISA法测定两组患者血清MMP-9的水平。结果奥扎格雷钠组的总有效率明显高于常规治疗组(P<0.05)。两组患者治疗后MMP-9水平均明显下降,奥扎格雷钠组降低更明显(P<0.05)。结论奥扎格雷钠注射液可能通过下调血清MMP-9的表达发挥脑保护的作用从而提高对急性脑梗死患者治疗的疗效。
Objective To observe the clinical efficacy of ozagrel sodium injection in patients with acute cerebral infarction and its effect on the level of serum MMP-9. Methods Sixty-five patients with acute cerebral infarction were randomly divided into two groups: the ozagrel sodium group (n = 31) and the conventional treatment group (n = 34). Both groups were given routine treatment. Ozagrel sodium group Day 2 intravenous infusion, treatment 14d. Serum MMP-9 levels were measured by ELISA in two groups. Results The total effective rate of ozagrel sodium group was significantly higher than that of conventional treatment group (P <0.05). After treatment, the levels of MMP-9 in both groups were significantly decreased, while those in ozagrel sodium group decreased more significantly (P <0.05). Conclusion Ozagrel sodium injection may exert the effect of cerebral protection by decreasing the expression of serum MMP-9, so as to improve the curative effect on the patients with acute cerebral infarction.